Table 6 CAR-T cell based therapies. R/R relapsed/refractory, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndrome, CML chronic myeloid leukemia, MPN myeloproliferative neoplasm, alloHSCT allogeneic hematopoietic stem cell transplantation, RAEB refractory anemia with excess blasts, MM multiple myeloma

CD33

NCT03126864

I

R/R AML

NCT02799680

I

R/R AML

NCT01864902

I/II

R/R AML

NCT02944162

I/II

R/R AML

NCT03291444

I

R/R AML, MDS; ALL

NCT03473457

n.a.

R/R AML

NCT03222674

I/II

AML

CD38

NCT03291444

I

R/R AML, MDS; ALL

NCT03473457

n.a

R/R AML

NCT03222674

I/II

AML

CD123

NCT03585517

I

AML

NCT03114670

I

Recurred AML after alloHSCT

NCT03556982

I/II

R/R AML

NCT02623582

I

R/R AML

NCT02159495

I

R/R AML

NCT03672851

I

R/R AML

NCT03766126

I

R/R AML

NCT03291444

I

R/R AML, MDS; ALL

NCT03473457

n.a

R/R AML

NCT03796390

I

R/R AML

NCT03222674

I/II

AML

UCART123

NCT03190278

I

R/R AML

NCT01864902

I

R/R AML, high-risk AML

CD123/CLL1

NCT03631576

II/III

R/R AML

CD33/CLL1

NCT03795779

I

R/R AML, MDS, MPN, CML

CCL1

NCT03222674

I/II

AML

Lewis Y

NCT01716364

I

Myeloma, AML, MDS

WT1

NCT03291444

I

R/R AML, ALL, MDS

CD7/NK92

NCT03018405

I/II

R/R AML

NKG2D

NCT02203825

I

AML, MDS-RAEB, MM

NCT03018405

I/II

R/R AML, AML, Myeloma